We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
51
Arcus Biosciences
RCUS
$3.71B
$9.76M 0.4%
451,983
-260,000
-37% -$5.62M
TNGX icon
52
Tango Therapeutics
TNGX
$4.72B
$9.41M 0.38%
450,000
+440,000
+4,400% +$6.12M
EOLS icon
53
Evolus
EOLS
$382M
$9.23M 0.37%
2,245,360
+1,175,360
+110% +$5.7M
SOPH icon
54
SOPHiA GENETICS
SOPH
$545M
$9.16M 0.37%
+1,850,000
New +$9M
ELVN icon
55
Enliven Therapeutics
ELVN
$3.88B
$9.05M 0.37%
230,869
-794,131
-77% -$22M
INBX icon
56
Inhibrx
INBX
$1.29B
$8.81M 0.36%
131,000
+106,000
+424% +$7.86M
DXCM icon
57
DexCom
DXCM
$28.8B
$8.79M 0.36%
140,000
-1,157,094
-89% -$80.6M
SEPN
58
Septerna Inc
SEPN
$1.52B
$6.61M 0.27%
275,000
-108,368
-28% -$2.85M
AVTX icon
59
Avalo Therapeutics
AVTX
$989M
$6.6M 0.27%
441,978
– –
BDSX icon
60
Biodesix
BDSX
$219M
$6.04M 0.24%
+416,599
New +$5.16M
RLMD icon
61
Relmada Therapeutics
RLMD
$556M
$5.86M 0.24%
+842,106
New +$3.98M
CGEM icon
62
Cullinan Oncology
CGEM
$1.11B
$5.83M 0.24%
+410,200
New +$5.27M
IMVT icon
63
Immunovant
IMVT
$8.12B
$5.71M 0.23%
230,000
-880,000
-79% -$22.8M
MBX
64
MBX Biosciences
MBX
$2.87B
$5.34M 0.22%
178,897
-230,003
-56% -$7.82M
IMUX icon
65
Immunic
IMUX
$206M
$5M 0.2%
+450,000
New +$4.03M
LRMR icon
66
Larimar Therapeutics
LRMR
$408M
$4.8M 0.19%
+1,066,960
New +$4.26M
ETON icon
67
Eton Pharmaceutcials
ETON
$1.18B
$4.11M 0.17%
+166,381
New +$2.91M
SABS icon
68
SAB Biotherapeutics
SABS
$278M
$4.02M 0.16%
+1,050,000
New +$4.19M
PRCT icon
69
Procept Biorobotics
PRCT
$1.05B
$4M 0.16%
+160,000
New +$4.51M
GPCR icon
70
Structure Therapeutics
GPCR
$3.51B
$3.86M 0.16%
80,000
-10,000
-11% -$684K
TECX
71
Tectonic Therapeutic
TECX
$619M
$3.76M 0.15%
+121,684
New +$2.99M
LUNG icon
72
Pulmonx
LUNG
$53.6M
$3.6M 0.15%
2,788,323
+750,000
+37% +$1.24M
IOVA icon
73
Iovance Biotherapeutics
IOVA
$2.45B
$3.51M 0.14%
+1,000,000
New +$3.2M
ARGX icon
74
argenx
ARGX
$54.7B
$2.56M 0.1%
3,500
-28,226
-89% -$22.1M
KPTI icon
75
Karyopharm Therapeutics
KPTI
$178M
$2.45M 0.1%
440,000
– –
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.